altu-135

Recombinant proteinexperimental

Clinical trial activity

8 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
7
Phase 3
6
Phase 4
1

Earliest trial started Jun 1, 2004 (NCT00095732)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • altu-135
  • altu-135
  • altu-135
  • liprotamase
  • liprotamase
  • liprotamase lipase
  • theraclec
  • trizytek

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03051490Phase 3Apr 28, 2017Anthera Pharmaceuticals
NCT02823964Phase 4Sep 1, 2016Anthera Pharmaceuticals
NCT02734810Phase 3Jun 1, 2016Anthera Pharmaceuticals
NCT02279498Phase 3Jun 1, 2015Anthera Pharmaceuticals
NCT00500084Phase 3Dec 1, 2007Anthera Pharmaceuticals
NCT00449904Phase 3Jun 1, 2007Anthera Pharmaceuticals
NCT00449878Phase 3May 1, 2007Anthera Pharmaceuticals
NCT00095732Phase 2Jun 1, 2004Anthera Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Anthera PharmaceuticalsFor profit8832004
Cystic Fibrosis Foundation TherapeuticsAcademic/Hospital1012004
2 organizations
Page 1 / 1